Cathie Wood's ARK doubles down on Intellia bet again

Cathie Wood's ARK funds made just one trade on Thursday, adding 56,769 shares of Intellia Therapeutics across ARKK and ARKG. The CRISPR-focused biotech is up more than 30% year-to-date and is heading for its best week since October. Despite prior setbacks in 2025, ARK continues to build conviction in the gene-editing firm.